SCHEMBL31246020

SCHEMBL31246020

COC(=O)c1ccc(OC2CC(N(C)C(=O)OC(C)(C)C)C2)c(Br)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOTUM Q6P988 2/20 0.43
▸ ALDH1A1 P00352 3/20 0.36
▸ MAPT P10636 3/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ ALOX12 P18054 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ ESRRA P11474 1/20 0.35
▸ CHRNB2 P17787 1/20 0.34
▸ CHRNA4 P43681 1/20 0.34
▸ AAK1 Q2M2I8 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ UCHL1 P09936 1/20 0.34
▸ USP30 Q70CQ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31246029 0.89 KMT2A (0.36) ALDH1A1CYP1A2CYP2C19RAB9AKMT2A
SCHEMBL31245985 0.81 NOTUM (0.41) NOTUMALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL27391574 0.81 NOTUM (0.41) NOTUMALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL27391578 0.78 PDE4D (0.46) KDM4EGPR119PDE4APDE4BPDE4C
SCHEMBL30824880 0.78 PDE4D (0.46) KDM4EGPR119PDE4APDE4BPDE4C
SCHEMBL31245970 0.77 PDE4D (0.42) ALDH1A1CYP1A2CYP2C19CYP2C9SMN1; SMN2
SCHEMBL27391576 0.77 NOTUM (0.46) NOTUMALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL16533471 0.76 NOTUM (0.50) NOTUMALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL31245974 0.76 NOTUM (0.45) NOTUMALDH1A1MAPTCYP1A2CYP3A4
SCHEMBL30811962 0.75 PDE4D (0.51) KMT2AGPR119PDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702022-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE Halda Therapeutics Opco, Inc. (US) 2026-03-04 — — EP disclosed
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO INC (US) 2026-01-29 — — US disclosed
WO-2024211684-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2024-10-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028338-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, HCCS NOTUM 4127/4885ALDH1A1 211/4885MAPT 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback